What are the latest figures on the superdisintegrants market’s size and projected CAGR?
The superdisintegrants market size has grown strongly in recent years. It will grow from $1.09 billion in 2024 to $1.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to the rising prevalence of chronic and lifestyle-related diseases, growth in the global pharmaceutical industry, increasing demand for orally disintegrating tablets (ODTs), growing geriatric and pediatric populations, and rising focus on improving bioavailability of drugs.
The superdisintegrants market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising demand for oral solid dosage forms, growth in chronic disease prevalence, expanding pharmaceutical manufacturing, growth in chronic disease prevalence, and increasing demand for oral solid dosage forms. Major trends in the forecast period include technological integration in manufacturing, advancements in co-processed excipients shifting toward natural and biodegradable superdisintegrants, the development of novel drug-delivery systems, and collaboration between excipients and pharmaceutical companies.
Get Your Free Sample of The Global Superdisintegrants Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21292&type=smp
Which Market drivers have played a significant role in driving the superdisintegrants market?
Increasing generic drug production is expected to propel the growth of the superdisintegrants market going forward. A generic drug is a medication that has the same active ingredients, dosage, strength, route of administration, quality, and performance as a brand-name drug but is typically sold at a lower cost. Increasing generic drug production is driven by the rising demand for affordable medications, patent expirations of branded drugs, and government initiatives to reduce healthcare costs. Superdisintegrants in generic drugs enhance tablet disintegration and dissolution, ensuring faster drug release, improved bioavailability, and better patient compliance. For instance, in January 2023, according to a report published by the Food and Drug Administration, a US-based government department, in 2022 it was estimated that 91% of prescriptions in the United States were filled with generic drugs, with over 32,000 generic medications having been approved by the Food and Drug Administration to date. Therefore, the increasing generic drug production is driving the growth of the superdisintegrants market.
What are the key segments within the superdisintegrants market?
The superdisintegrants market covered in this report is segmented –
1) By Type: Natural Superdisintegrants, Synthetic Superdisintegrants, Other Superdisintegrants
2) By Formulation: Tablets, Capsules
3) By Therapeutic Area: Gastrointestinal Diseases, Neurological Diseases, Oncology, Infectious Diseases, Cardiovascular Diseases, Hematological Diseases
Subsegments:
1) By Natural Superdisintegrants: Starch, Cellulose, Chitosan, Gums, Other Natural Superdisintegrants
2) By Synthetic Superdisintegrants: Cross-linked Polyvinylpyrrolidone (Crospovidone), Sodium Starch Glycolate, Croscarmellose Sodium, Other Synthetic Superdisintegrants
3) By Other Superdisintegrants: Ion Exchange Resins, Surfactant-Based Superdisintegrants, Other Specialized Superdisintegrants
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/superdisintegrants-global-market-report
Which key players are shaping the superdisintegrants market?
Major companies operating in the superdisintegrants market are BASF SE, Merck KGaA, DuPont de Nemours Inc., IFF Pharma Solutions, Ingredion Incorporated, Roquette Freres SA., FMC Corporation, Azelis Group, Ashland Inc., Piramal Healthcare, Colorcon Inc. Ltd., Boai NKY Pharmaceuticals Ltd., JRS Pharma, Faran Shimi Pharmaceutical, DFE Pharma India Private Limited., Sigachi Industries Limited, Corel Pharma Chem, Maple Biotech Pvt. Ltd., Shanghai Chineway Pharmaceutical Technology Co. Ltd., JH Nanhang Life Sciences Co. Ltd.
Which transformative trends will shape the superdisintegrants market landscape?
Major companies operating in the superdisintegrants market are focusing on novel offerings, such as multifunctional disintegrants, to enhance drug formulation efficiency, improve tablet disintegration speed, and optimize patient compliance in pharmaceutical applications. A multifunctional disintegrant is an advanced excipient that combines disintegration, binding, and flow-enhancing properties to improve tablet formulation efficiency and drug release. For instance, in June 2023, Ashland Inc., a US-based chemicals company, launched Polyplasdone Plus, a co-processed multifunctional direct compression superdisintegrant designed to enhance tablet disintegration, powder flow, and lubrication during pharmaceutical manufacturing. This innovation simplifies production by eliminating two manufacturing steps, improving tablet hardness, and supporting high-speed and continuous manufacturing processes.
How do regional factors impact the superdisintegrants market, and which region is the largest contributor?
North America was the largest region in the superdisintegrants market in 2024. The regions covered in the superdisintegrants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Superdisintegrants Market Report 2025 Offer?
The superdisintegrants market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Superdisintegrants are pharmaceutical excipients specifically designed to enhance the disintegration of tablets or capsules, facilitating faster release and absorption of the active pharmaceutical ingredient (API) in the body. They are crucial for improving the bioavailability of drugs and ensuring their efficacy, especially in orally administered medications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21292
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
